The development of therapeutic cancer vaccines has long been a promising yet challenging field of research. While early efforts were impeded by limited efficacy and immune escape, recent advances in immunotherapy, mRNA technology and tumor antigen discovery have sparked renewed interest in cancer vaccine development. What is the current state of the field, and how should we address the remaining challenges to bring therapeutic cancer vaccines to the clinic? Which modalities hold potential, and what might the future of therapeutic cancer vaccines look like?
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Weber, J. S. et al. Lancet 403, 632–644 (2024).
Rojas, L. A. et al. Nature 618, 144–150 (2023).
McNeil, L. K. et al. J. Immunother. Cancer https://doi.org/10.1136/jitc-2024-SITC2024.1473 (2024).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marchal, I. Cancer vaccines: the experts speak. Nat Biotechnol 43, 477–481 (2025). https://doi.org/10.1038/s41587-025-02606-y
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41587-025-02606-y
